Cross-border Life Protection: Ludaobei Hospital's BCMA CAR-T Therapy Helps Russian Patient Achieve Deep Remission

Multiple myeloma (MM) is a challenging hematologic malignancy that often progresses after multiple lines of treatment. CAR-T cell therapy, an emerging immunotherapy, has given new hope to these patients. Recently, a Russian patient with relapsed/refractory MM achieved deep remission after receiving autologous BCMA CAR-T therapy at Yanda Ludaobei Hospital, reigniting their hope for life.

In March 2023, the patient, "Khramov" (pseudonym), was diagnosed with multiple myeloma. Despite undergoing chemotherapy, autologous stem cell transplant, and consolidation therapy, his condition progressed by June 2025, with elevated levels of λ free light chains in his serum. Seeking more effective treatment, Khramov traveled to Yanda Ludaobei Hospital from Russia.

After detailed assessments and tests, Dr. Junfang Yang's team decided to treat him with autologous BCMA CAR-T cells. The therapy went smoothly with only mild cytokine release syndrome (CRS), which was promptly managed. Within 19 days, key biomarkers, including λ chains, were negative, and his condition was almost normalized. After 29 days, an MRD test showed no malignant cells, and PET/CT scans showed significant improvement, indicating complete remission.

Dr. Yang’s team provided a detailed follow-up plan for Khramov, ensuring continued monitoring and care once he returned to Russia. Khramov expressed his excitement about returning to China for another check-up in two months, with plans to tour the country that gave him a second chance at life.

Key Insights

• BCMA CAR-T therapy is proving to be an effective treatment for relapsed/refractory multiple myeloma (R/R MM), especially for high-risk patients.

• The therapy showed impressive results, including complete remission and the reduction of disease-related biomarkers.

• International medical services at Ludaobei Hospital provide top-tier, patient-centered care, making advanced treatments accessible to patients worldwide.